CRISPR Delivered Anti-BCMA CAR-T

A Phase 1b Clinical Trial of CRISPR Delivered Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Multiple Myeloma

Arms / Cohorts

Experimental:Dose Escalation: Planned Dose

Accepting patients

Experimental:Dose Expansion: Maximum Tolerated Dose

Accepting patients

Experimental:Dose Escalation: Starting Dose

Accepting patients

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.